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Abstract
Background
In Latin America, community-acquired pneumonia remains a major cause of morbidity and
mortality among children. Few studies have examined the etiology of pneumonia in Ecuador.
Methods
This observational study was part of a randomized, double blind, placebo-controlled clinical
trial conducted among children aged 2–59 months with severe pneumonia in Quito, Ecua-
dor. Nasopharyngeal and blood samples were tested for bacterial and viral etiology by poly-
merase chain reaction. Risk factors for specific respiratory pathogens were also evaluated.
Results
Among 406 children tested, 159 (39.2%) had respiratory syncytial virus (RSV), 71 (17.5%)
had human metapneumovirus (hMPV), and 62 (15.3%) had adenovirus. Streptococcus
pneumoniae was identified in 37 (9.2%) samples and Mycoplasma pneumoniae in three
(0.74%) samples. The yearly circulation pattern of RSV (P = 0.0003) overlapped with S.
pneumoniae, (P = 0.03) with most cases occurring in the rainy season. In multivariable anal-
ysis, risk factors for RSV included younger age (adjusted odds ratio [aOR] = 1.9, P = 0.01)
and being underweight (aOR = 1.8, P = 0.04). Maternal education (aOR = 0.82, P = 0.003),
pulse oximetry (aOR = 0.93, P = 0.005), and rales (aOR = 0.25, P = 0.007) were associated
with influenza A. Younger age (aOR = 3.5, P = 0.007) and elevated baseline respiratory rate
were associated with HPIV-3 infection (aOR = 0.94, P = 0.03).
Conclusion
These results indicate the importance of RSV and influenza, and potentially modifiable risk
factors including undernutrition and future use of a RSV vaccine, when an effective vaccine
becomes available.
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Introduction
Pneumonia is the leading infectious cause of mortality among children below 5 years of age,
and is responsible for nearly one million deaths annually in this population [1–3]. The World
Health Organization (WHO) estimates that the vast majority (over 95%) of the estimated 156
million pneumonia episodes occurring each year among young children takes place in devel-
oping countries [4]. Globally, South Asia and sub-Saharan Africa bear the highest burden of
pneumonia episodes; fifteen countries within these two regions alone accounted for over two-
thirds of pneumonia mortality in 2011 [5–7]. Nevertheless, in Latin America and the Carib-
bean, community-acquired pneumonia continues to be a prominent cause of high morbidity
and mortality among children. Specifically, an estimated 327,000 cases and 12,000–28,000
deaths due to pneumonia occur annually in children in this region [8,9].
Hospital-based studies have contributed to understanding the causes of pneumonia in
developing countries [4]. However, determining pneumonia etiology remains challenging due
to difficulties in obtaining lower respiratory tract specimens from children [1,10]. The most
significant bacterial strains associated with pneumonia in children described in past microbio-
logical studies include Streptococcus pneumoniae and Haemophilus influenzae type B (Hib),
[11–13] followed by Staphylococcus aureus and Mycoplasma pneumoniae [14]. Furthermore,
viral pathogens linked to acute respiratory infections, including pneumonia, include human
metapneumovirus (hMPV), adenovirus, influenza types A and B, rhinovirus, respiratory syn-
cytial virus (RSV), and bocavirus [15,16].
Studies examining the etiology of pneumonia in Latin America, in particular Ecuador, are lim-
ited. Using blood and lung aspirates from children younger than 5 years from tertiary care hospi-
tals in Bangladesh, Ecuador, India, Mexico, Pakistan, Yemen, and Zambia, bacterial pathogens
associated with WHO-defined very severe pneumonia were: S. pneumoniae and S. aureus, fol-
lowed less commonly by H. influenzae, Escherichia coli, and Pseudomonas aeruginosa [17]. How-
ever, the study conducted by Asghar et al [17] did not assess viral pathogens other than RSV.
As immunization programs have been implemented within developing countries to protect
against bacterial pneumonia, viral pathogens have also emerged as prevalent etiologic agents
[18]. Specifically, the need for more etiology studies in countries that have introduced both
Hib and pneumococcal conjugate vaccines has been recognized in order to define the new dis-
tribution of pneumonia etiologies that will help inform future treatment and prevention
approaches [12]. In Ecuador, the pneumococcal conjugate vaccine, PCV10, and Hib vaccina-
tions have been introduced, with WHO-UNICEF estimates showing widespread uptake [19].
We recently conducted a trial investigating zinc as an adjunct treatment for severe pneumo-
nia among children in Quito, Ecuador [20] and systematically collected blood and nasopharyn-
geal samples from participants to determine pneumonia etiology. This manuscript describes the
epidemiological characteristics and etiology of pneumonia in this study population.
Materials and methods
This observational study was performed within the context of a randomized, double blind pla-
cebo-controlled clinical trial conducted among children with severe pneumonia, designed to
measure the efficacy of daily zinc administration until hospital discharge on the duration of
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pneumonia symptoms [20]. The original study took place from February 2008 to April 2010 at
the Baca Ortiz Hospital in Quito, Ecuador (altitude 2,830 meters) [21]. As the main pediatric
referral hospital in Ecuador, Baca Ortiz has approximately 130,000 outpatient and emergency
consultations annually, and the most common reason for hospitalization is acute lower respi-
ratory tract infection (ALRI). The Boston University Institutional Review Board and Ethics
Committee of the Corporacio´n Ecuatoriana de Biotecnologı´a both approved the study. Writ-
ten informed consent was obtained from each child’s parent or care provider. The Ethics Com-
mittee of the Corporacio´n Ecuatoriana de Biotecnologı´a served as the Data Safety Monitoring
Board in order to ensure proper management and protection of study participants.
Eligibility criteria
Children aged 2–59 months with severe pneumonia were eligible for participation if parental
written informed consent was provided. A resident physician entrusted to screen potential
study subjects evaluated each child presenting with respiratory symptoms in the emergency
room. If the child was considered eligible, a senior study physician conducted a rapid hemo-
globin test and complete clinical examination. If the child met the eligibility criteria and was
confirmed to have pneumonia, the study physician enrolled the child after obtaining informed
consent from the child’s care provider.
Enrollment was based on the presence of cough and/or difficulty breathing, tachypnea
(50 breaths per minute in children from two to12 months of age;40 breaths per minute
in children aged>12 to 59 months), hypoxemia assessed by pulse oximetry (SpO2 <90%) and
at least one of the following: rales, wheezing, diminished breath sounds, bronchial breath
sounds or pleural rub. Exclusion factors were marasmus or kwashiorkor, measles, pneumonia
due to aspiration of a foreign body, hepatic or renal disease, sepsis, congenital abnormalities
(cardiac, renal, or genetic), complicated pneumonia (lung abscess, pleural effusion, pneumato-
cele, atelectasis), very severe pneumonia (using WHO criteria: tachypnea, chest wall indrawing
and central cyanosis or inability to drink), severe anemia (hemoglobin below 8 g/dL), and
refusal of the primary care provider to provide written informed consent.
At the time of enrollment, study physicians conducted a detailed clinical evaluation consist-
ing of height, weight, respiratory rate, oxygen saturation, axillary temperature, and chest
indrawing. Baseline testing also included the following: 1) collection of blood to measure C-
reactive protein (CRP), plasma zinc, whole-blood polymerase chain reaction (PCR) for Strep-
tococcus pneumoniae and Hib; 2) pulse oximetry; 3) nasopharyngeal aspirate for PCR analysis
of atypical bacteria and viruses; and 4) chest X-ray. Study physicians additionally gathered
information on demographic characteristics, current illness, and medical history. Further
information regarding enrollment and clinical procedures, as well as complete details of fol-
low-up, treatment, randomization, sample size, and clinical procedures are described else-
where [20].
Laboratory analyses
At enrollment, blood samples from participants were acquired by venipuncture; hemoglobin
was measured using a portable HemoCue Hb 201+ machine (HemoCue, Angelholm, Sweden).
As recommended by the WHO, a nasopharyngeal swab was also obtained [22]. Samples were
stored at -20˚C until processed, in batches during the study. Blood and respiratory samples
were transported to the lab following a cold chain protocol.
DNA was extracted from blood samples using the QIAamp DNA blood mini kit (Qiagen,
Venlo, Netherlands) according to manufacturer instructions. DNA and RNA were extracted
from nasopharyngeal swabs using the HP viral nucleic acid kit (Roche, Basel, Switzerland)
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according to manufacturer instructions. Extreme DNA/RNA isolation precautions were
observed. Leftover clinical samples were stored at -80˚C. DNA/RNA quantity and quality were
determined by absorbance 260/280 in the spectrophotometer Perkin Elmer and fluorescence
by QuantIT (Invitrogen, Waltham, USA). PCR for a housekeeping human gene was used as a
succesful extraction control.
Polymerase Chain Reaction (PCR) of blood samples
Nested PCR for S. pneumoniae was performed in DNA isolated from blood samples [23]. A
preliminary in vitro study confirmed that the lower limit of detection was10 colony-forming
units/mL [24], while the specificity among control subjects with no identifiable respiratory dis-
orders was 100%. Finnish investigators demonstrated that the same pneumolysin primers had
100% specificity when tested in vitro for a variety of pathogens [23]. Genomic DNA ATCC
BAA-255D-5 S. pneumoniae was used as a positive PCR amplification control. PCR for H.
influenzae was performed in DNA isolated from blood using Strain ATCC 33533 H. influenzae
as a control [25].
Nasopharyngeal (NP) swab PCR
M. pneumoniae PCR was performed in DNA isolated from NP swabs [26,27], using Genomic
DNA ATCC 15531D M. pneumoniae strain FH as a positive PCR amplification control [28].
Real-time PCR kits, LightMix-40-0303-16, were used for detection of adenovirus, LightMix
40-0222-16 for the detection of Chlamydophila pneumoniae, LightMix 40-0225-16 for detec-
tion of influenza virus A and B, LightMix 40-0223-16 for detection of parainfluenza virus 1, 2,
and 3, LightMix 40-0184-16 for detection of hMPV, and LightMix for detection of RSV were
purchased from TibMolBiol (Alelphia, USA). All kits were evaluated and standardized; detec-
tion was performed according to manufacturer instructions.
Data management
The study supervisor checked project-specific case report forms twice weekly for complete,
discrepant, inappropriate, and illogical responses. Double data entry was performed with
Microsoft Access 2000 (Redmond, WA). SPSS (version 11.5.0 program SPSS Inc., Chicago, IL)
was used for validation and cleaning, and SAS 9.3 was used for all analyses.
Data analysis
Descriptive analysis was conducted for all baseline demographic and clinical characteristics.
Frequencies, proportions, means, medians, and interquartile range, as appropriate, were
reported. For comparison purposes, etiological characteristics were stratified by the age catego-
ries of less than one year and 1–5 years. Chi-squared tests and Pearson correlation coefficients
were used to detect differences between proportions and associations among baseline charac-
teristics and etiology. To describe seasonality, both viral and bacterial infections were analyzed
by monthly distribution, with parainfluenza types 1, 2, and 3 merged into one category, and
influenza types A and B combined. Chi-squared tests were used to detect differences in
monthly case distribution for each respective pathogen.
In order to identify potential risk factors, the association of demographic and clinical char-
acteristics with each pathogen was assessed using univariate and multivariable logistic regres-
sion; odds ratios (ORs), adjusted odds ratios (aORs), and 95% confidence intervals (CIs) were
calculated. Backward selection with entry criteria of α = 0.02 was used to assess variables for
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inclusion in multivariable logistic regression models. All analyses were conducted using two
tail tests at a significance level of α = 0.05.
Results
Of 450 enrolled children, 406 (90.2%) had blood or nasopharyngeal samples taken, and were
subsequently analyzed to determine etiology. Samples were analyzed for bacterial pathogens,
viral pathogens, and co-infection with bacterial and viral pathogens (Fig 1). Bacteria or viruses
were not detected in 109 (26.8%) of the 406 samples. Only 403 samples were tested for S. pneu-
moniae; 299 samples were tested for H. influenzae. The median age was 9.48 months; 58.6%
were less than one year (Table 1). Just over half (54.2%) were male. Among all participants,
190 (46.9%) presented with fever, 77 (19.2%) were underweight, and 70 (18.1%) were stunted.
Viral etiology
Of 406 participants screened, the most common viral isolate was RSV (n = 159; 39.2%), fol-
lowed by hMPV (n = 71; 17.5%), adenovirus (n = 62; 15.3%), and parainfluenza virus (n = 57;
Fig 1. Study profile and analysis of sample pathogens.
doi:10.1371/journal.pone.0171687.g001
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14.0%) (Table 2). Among 40 (9.9%) children who tested positive for influenza, 29 had influenza
type A and 11 had influenza type B. Among children with human parainfluenza, 15 tested pos-
itive for type 1, 7 for type 2, and 35 for type 3.
Table 1. Baseline characteristics of children with severe pneumonia (N = 406).
Baseline Characteristics
Age 9.48 ± 12.16 months
< 1 year 238 (58.6%)
1–5 years 168 (41.4%)
Gender
Male 220 (54.2%)
Household Characteristics
Years of maternal education 9 ± 6
Number of people in household 4 ± 2
Number of rooms in household 2 ± 2
Breastfeeding 275 (67.7%)
Clinical Characteristics
Initial temperature1 (˚C) * 37.6 ± 0.9
Proportion with fever1 ** 190 (46.9%)
Weight-for-age z (WAZ) score 2 -1.0 ± 1.5
Height-for-age z (HAZ) score 3 -0.8 ± 1.7
Underweight (WAZ -2) 2 77 (19.2%)
Stunting (HAZ -2)4 70 (18.1%)
Initial respiratory rate (breaths/min) 58.0 ± 9
Respiratory signs: 1
• Pulse oximetry (% SO2)
• Rales
• Bronchial breath sounds
• Pleural rub
• Whistle
• 80 ± 6.0
• 363 (89.6%)
• 48 (11.8%)
• 5 (1.2%)
• 66 (16.3%)
Before presentation to hospital:
• Vaccinated5
• Provided with antibiotic6
• Provided with bronchodilator6
• 305 (75.9%)
• 27 (56.3%)
• 40 (34.7%)
Chest X-ray findings: 7
• Infiltrate
• Consolidation
• Air trapping
• Other***
• 255 (65.9%)
• 14 (3.6%)
• 54 (14.0%)
• 64 (16.5%)
All values are n (%) and median ± IQR. Variability in sample size of characteristics due to missing
responses:
1n = 405
2n = 401
3n = 394
4n = 386
5n = 402
6n = 403
7n = 387
*Mean and standard deviation.
**Fever (temperature 37.5˚C).
***Other includes pneumothorax and necrosis.
doi:10.1371/journal.pone.0171687.t001
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Significant differences across age category among viral pathogens were found for RSV and
human parainfluenza type 3 (HPIV-3) (Table 2). Of the 159 children who tested positive for
RSV, 105 (66.0%) were less than one year old. These children had 1.67 times the odds of RSV
infection compared to children aged 1–5 years (95% CI, 1.10, 2.52; P = 0.015). Of the 35 chil-
dren who tested positive for HPIV-3, 27 (77.1%) were aged less than one year. These younger
children had 2.56 (95% CI, 1.13, 5.78; P = 0.02) times the odds of HPIV-3 relative to children
aged 1–5 years. The odds of infection did not differ by sex for any viral pathogen.
Bacterial etiology
S. pneumoniae was the most common bacterial pathogen isolated (9.2%; 37/403) followed by
M. pneumoniae (0.74%; 3/406). Testing of the bacterial pathogen H. influenzae was discontin-
ued after finding zero positive samples among 299 tested. There were no significant differences
across age category for either bacterial pathogen.
Co-infection by both bacterial and viral pathogens
Co-infection with more than one pathogen was present in 25.6% (103/403) of children. Of
these 103 participants, 78 (75.7%) displayed co-infection with two pathogens, 22 (21.4%) with
three pathogens, two (1.9%) with 4 pathogens, and one (0.97%) with 5 pathogens. The most
common dual infection combinations were RSV and hMPV in 20 (19.4%), adenovirus and
RSV in 14 (13.6%), S. pneumoniae and RSV in 9 (8.7%), HPIV-3 and RSV in 7 (6.8%), influ-
enza A and adenovirus in 3 (2.9%), and S. pneumoniae and adenovirus in 3 (2.9%). The most
prevalent triple infection combinations were the following: hMPV, adenovirus and RSV in 5
(4.9%); S. pneumoniae, hMPV and RSV in 3 (2.9%); hMPV, HPIV-3 and RSV in 3 (2.9%); and
hMPV, influenza A and RSV in 2 (1.9%). Two participants were infected with 4 pathogens:
RSV, hMPV, S. pneumoniae, and HPIV-2 were isolated in one individual; hMPV, HPIV-2,
HPIV-3, and RSV were isolated in the other. One participant was found to have bacterial and
viral co-infection with 5 pathogens. The pathogens isolated from this individual included S.
Table 2. Pneumonia etiology by age category.
Age Group N (%) Total (N = 406)*
Viral Pathogens < 1 year (n = 238) 1 to 5 years (n = 168)
Adenovirus 35 (14.7%) 27 (16.1%) 62 (15.3%)
Influenza 40 (9.9%)
Type A 16 (6.7%) 13 (7.7%) 29 (7.1%)
Type B 7 (2.9%) 4 (2.4%) 11 (2.7%)
Parainfluenza 57 (14.0%)
Type 1 10 (4.2%) 5 (3.0%) 15 (3.7%)
Type 2 3 (1.3%) 4 (2.4%) 7 (1.7%)
Type 3 27 (11.3%) 8 (4.8%) 35 (8.6%)
Human metapneumovirus 40 (16.8%) 31 (18.5%) 71 (17.5%)
Respiratory syncytial virus 105 (44.1%) 54 (32.1%) 159 (39.2%)
Bacterial Pathogens
Streptococcus pneumoniae (n = 403) 20 (8.5%) 17 (10.1%) 37 (9.2%)
Mycoplasma pneumoniae 0 (0%) 3 (1.8%) 3 (0.74%)
**Haemophilus influenzae (n = 299) 175 (58.5%) 124 (41.5%) 0 (0%)
*There were 406 total nasopharyngeal samples for respiratory viruses and M. pneumoniae, 403 for S. pneumoniae and 299 for H. influenzae.
**Since all 299 H. influenzae samples were found to be negative, the frequencies for age category represent those children that had samples taken.
doi:10.1371/journal.pone.0171687.t002
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pneumoniae, hMPV, adenovirus, HPIV-3, and RSV. Multiple infections with S. pneumoniae in
combination with RSV, hMPV, adenovirus, influenza A and B, HPIV-2 and HPIV-3 were
detected in 27/403 (6.7%) samples. Of these 27 multiple co-infections, S. pneumoniae was most
commonly present with RSV in 14 samples, followed by hMPV in 9 samples, and adenovirus
in 6 samples. Dual infection with M. pneumoniae was present in 2 samples, containing RSV
and adenovirus.
Significant associations were present between infection by RSV and hMPV, RSV and influ-
enza A, as well as RSV and HPIV-1. Specifically, individuals infected with RSV had 1.90 (95%
CI, 1.13, 3.18; P = 0.014) times the odds of hMPV infection compared to individuals without
RSV. In contrast, individuals with influenza A had reduced odds of having RSV (0.23, 95% CI,
0.078, 0.67; P = 0.007) compared to individuals without influenza A. Furthermore, individuals
with HPIV-1 had reduced odds of having RSV (0.11, 95% CI, 0.014, .81; P = 0.03) compared to
those without HPIV-1 infection.
Seasonality
The climate of Quito consists of a dry (June to September) and rainy season (October to May).
Figs 2 and 3 exhibit the number of cases of viral and bacterial pathogens during specific
months of the year. The distribution of viral pathogens displays an increasing trend from
October to May. Specifically, the circulation of viral pathogens was greatest between January
and July, and lowest from July to August. Among all pathogens, RSV (P< 0.0001), parainflu-
enza (P< 0.0001), hMPV (P = 0.01), and S. pneumoniae (P = 0.03) significantly differed across
month of the year. RSV circulation was greatest between February and April, and moderate
between May and July with a slight peak in November (Fig 2). A similar circulation pattern
was displayed by hMPV, with the highest number of cases occurring between February and
May, and another peak in November. Parainfluenza cases were highest between May and July.
The circulation of S. pneumoniae was greatest between February and March, with moderately
high circulation from July to September (Fig 3). Circulation of M. pneumoniae was greatest
between February and June, and was negligible during other months.
Demographic and clinical risk factors associated with specific
pneumonia etiologies
Using backward selection, significant associations between baseline demographic and clinical
characteristics were found for hMPV, RSV, HPIV-3, and influenza A. In univariate analysis,
decreased odds of influenza A infection was associated with maternal education (OR = 0.85,
95% CI, 0.76, 0.96; P = 0.001), pulse oximetry (OR = 0.93, 95% CI, 0.89, 0.97; P = 0.002), and
presence of rales (OR = 0.32, 95% CI, 0.13, 0.81; P = 0.02). For hMPV, participants treated
with a bronchodilator at baseline had 2.5 higher odds of infection compared to those without a
bronchodilator (95% CI, 1.5, 4.2; P = 0.0006). An increased odds of infection due to younger
age was associated with RSV (OR = 1.7, 95% CI, 1.1, 2.5; P = 0.02) and HPIV-3 (OR = 2.6, 95%
CI, 1.1, 5.8; P = 0.02).
Table 3 describes the multivariable analysis of demographic and clinical factors associated
with RSV, HPIV-3, influenza A, and hMPV. The following variables were included in the mul-
tivariable logistic regression models: younger age, maternal education, presence of bronchodi-
lator, fever, initial respiratory rate, underweight, pulse oximetry, and presence of rales.
Participants who were underweight (aOR = 1.8, 95% CI, 1.0, 3.1; P = 0.04) and aged less than
one year (aOR = 1.9, 95% CI, 1.2, 3.0; P = 0.01) had increased risk of RSV infection. Decreased
odds of influenza A infection was associated with increase in years of maternal education
(aOR = 0.82, 95% CI, 0.72, 0.94; P = 0.003), increase in oxygen saturation (aOR = 0.93, 95% CI,
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0.89, 0.98; P = 0.005), and presence of rales (aOR = 0.25, 95% CI, 0.09, 0.68; P = 0.007). Lastly,
for HPIV-3, elevated baseline respiratory rate was associated with reduced odds of infection
(aOR = 0.94, 95% CI, 0.88, 0.99; P = 0.03) whereas younger age was associated with increased
risk (aOR = 3.5, 95% CI, 1.4, 8.6; P = 0.007).
Discussion
There is a pressing need to better understand the etiology of pneumonia in children, especially
in resource-limited countries, in order to develop vaccines for prevention and more effective
treatments. This study is the first to describe the major viral and bacterial pathogens associated
with severe pneumonia among children living in the Andean region of Ecuador. The most
common viral pathogens were RSV, hMPV, adenovirus, and parainfluenza, findings consistent
with results from a household cohort study conducted in Peru [29,30]. Like the Peruvian study
[29], we found that RSV and hMPV were responsible for a substantial portion of lower respira-
tory infection etiology among young children, and co-infection by RSV and hMPV was com-
mon. The proportion of RSV (39.2%), hMPV (17.5%), and RSV-hMPV co-infection (4.9%)
detected in our entire sample was larger than a recent study conducted in Guatemala describ-
ing hMPV in 9%, RSV in 24%, and RSV-hMPV co-infection in 0.7% of ARI cases [31].
Fig 2. Seasonal distribution of viral pathogens among children with severe pneumonia between February 2008 and April 2010.
doi:10.1371/journal.pone.0171687.g002
Pneumonia etiology in Ecuadorian children
PLOS ONE | DOI:10.1371/journal.pone.0171687 February 9, 2017 9 / 19
Consistent with past research, younger age was a risk factor for HPIV-3 as well as RSV [32–
34]. HPIV serotypes 1, 2, and 3 are common etiologic agents of respiratory illness, but HPIV-3
frequently is associated with severe pneumonia in young infants [35,36]. Since RSV and
HPIV-3 infect children in the first few months of life, our findings highlight the need for a vac-
cine against RSV and HPIV-3 for use in early infancy.
In Ecuador, October-May comprises the rainy or winter season, and June-September the
dry or summer season. Studies conducted in Colombia and Brazil describe the climactic
impact of rainfall on viral pneumonia circulation, and showed that the circulation of RSV and
hMPV was greatest during the late winter months that encompass the rainy season [37,38]. In
our study, RSV and hMPV showed similar seasonality patterns with more cases in February-
May and moderate peaks between June and July. Our findings of seasonality are further sub-
stantiated by epidemiological monitoring conducted by PAHO, which describes peak RSV
activity within the months of March-May specifically in the Andean region [39].
Furthermore, the seasonality observed in this work is similar to studies of bacteremic pneu-
mococcal pneumonia coinciding with viral pneumonia, which described a greater number of
cases in late winter [40,41]. Specifically, circulation of S. pneumoniae was highest during Feb-
ruary-March with moderate peaks between July and September, which overlapped with RSV
and hMPV cases. Weinberger et al [41] described the parallel pattern of RSV and S.
Fig 3. Seasonal distribution of bacterial pathogens among children with severe pneumonia between February 2008 and April 2010.
doi:10.1371/journal.pone.0171687.g003
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pneumoniae as providing new information that may help to understand and predict the poten-
tial impact of new vaccines.
Current evidence implicates multiple pathogen infection involving viral and bacterial-viral
etiologic agents with severe pneumonia [18]. In our study, 18.0% of children had triple viral
infection, which is in agreement with a recent review that found dual or triple viral infection
detected among 10–20% of children with pneumonia [42]. Interestingly, co-infection by S.
pneumoniae was present with all viral pathogens with the exception of HPIV-1 (although there
were relatively few HPIV-1 isolates), in combination with two, three, and four other viral path-
ogens. The most frequent combination that we detected was S. pneumoniae with RSV. Similar
circulation patterns and co-infection between these two pathogens inspires further study into
the interaction between these two causative agents, which has been under investigation in vivo
and in vitro [43,44]. Overall, the interaction between bacterial and viral pathogens in terms of
temporality and severity of childhood pneumonia is unclear and merits further investigation
[45]. Ultimately, understanding these infection patterns among communities in developing
countries is vital to implementing effective strategies to prevent pneumococcal pneumonia
[46,47].
In Ecuador, the Hib and pneumococcal conjugate (PCV) vaccines were introduced in 2003
and 2010, respectively [19]. Specifically, PCV7 was introduced in the Ecuador national immu-
nization program in 2010, which was then replaced by PCV10 in 2011 [48–50]. PCV has been
recommended for infants at 2, 4, and 6 months, and recent WHO-UNICEF report estimates
describe an increase in vaccine uptake from 2% in 2009 to 81% in 2015 [19]. The absence of
Hib in our sample was likely due to use of the Hib vaccine. Hib vaccine uptake has been excel-
lent; a recent WHO report indicated that vaccine coverage increased from roughly 54% in
2003 to 99% in 2011, and to 87% in 2014 among children aged 12–23 months [19]. We discon-
tinued testing for Hib after the first 299 children, since no samples tested positive for the path-
ogen, a finding suggesting that this vaccine has had a major impact on Hib infection. The
limited detection of M. pneumoniae might have been due to the younger age of our study par-
ticipants. Recent studies have shown school-aged children to typically have a higher risk of
infection with M. pneumoniae in comparison to younger children and infants [51,52]. Recent
Table 3. Multivariable regression analysis of common pathogens by explanatory variables.
RSV (n = 159) HPIV-3 (n = 35) Influenza A (n = 29) hMPV (n = 71)
Characteristic Adjusted Odds Ratio (aOR)
(CI)
P Value aOR (CI) P value aOR (CI) P value aOR (CI) P value
Younger age 1.9 (1.2, 3.0) 0.01* 3.5 (1.4, 8.6) 0.007* 0.79 (0.36, 2.1) 0.58 1.0 (0.57, 1.9) 0.92
Maternal education 1.0 (0.96, 1.1) 0.58 1.1 (0.97, 1.2) 0.20 0.82 (0.72,
0.94)
0.003* 1.0 (0.93, 1.1) 0.87
Presence of
bronchodilator
1.1 (0.7, 1.7) 0.70 0.77 (0.35, 1.7) 0.51 0.55 (0.22, 1.4) 0.22 3.0 (1.7, 5.1) .0001*
Fever 1.2 (0.76, 1.8) 0.46 0.89 (0.42, 1.9) 0.77 1.1 (0.49, 2.6) 0.79 1.5 (0.87, 2.7) 0.14
Initial respiratory rate 1.02 (0.99, 1.1) 0.14 0.94 (0.88,
0.99)
0.03* 1.0 (0.97, 1.1) 0.43 0.99 (0.96,
1.03)
0.82
Underweight 1.8 (1.0, 3.1) 0.04* 1.5 (0.60, 3.9) 0.38 1.8 (0.71, 4.4) 0.22 0.98 (0.47, 2.1) 0.97
Pulse oximetry 0.99 (0.96, 1.0) 0.71 1.0 (0.97, 1.1) 0.43 0.93 (0.89,
0.98)
0.005* 1.0 (0.98, 1.07) 0.37
Rales 1.4 (0.67, 2.7) 0.39 2.0 (0.46, 9.0) 0.35 0.25 (0.09,
0.68)
0.007* 1.7 (0.63, 4.5) 0.31
Values that were significantly different (p<0.05) are indicated by the symbol *. The number of infections by RSV, HPIV-3, influenza A, and hMPV are smaller
than those presented in Table 2 because analysis was restricted to those for whom all baseline measurements were available.
doi:10.1371/journal.pone.0171687.t003
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reports have described a favorable reduction of community-acquired pneumonia and invasive
pneumococcal disease following PCV uptake among developing countries [18,53,54]. Simi-
larly, the development of an RSV vaccine is underway, tailored to target populations such as
infants, children, and pregnant mothers [55–57]. Hospitalization and morbidity due to RSV
among children in developing countries [58,59] strengthens the need for RSV vaccine imple-
mentation in Ecuador, and by extension the Andean region.
In Ecuador, the seasonal influenza vaccination was incorporated in the national immuniza-
tion schedule in 2006 [60], and estimates show 46% coverage among children 6 months-4
years as of 2015 [61,62]. The presence of influenza-associated severe pneumonia in developing
countries is important because influenza is potentially vaccine-preventable, and can predispose
to subsequent infection with other pathogens [15,63]. A study conducted in El Salvador [64]
described influenza virus among 6% of 608 cases of severe pneumonia, comparable to 9.9%
influenza and 3.4% influenza co-infection cases detected in our study. Given the presence of
this pathogen in Latin America, we believe that Ecuadorian children would benefit from
increased coverage of the influenza vaccine.
Recent studies have shown that severe pneumonia is more prevalent among high altitude
regions [65,66], and describe the impact of high altitude on hypoxemia and elevated respira-
tory rate [67–69]. In addition to age, undernutrition, lack of breastfeeding, and lack of mater-
nal education have also been described as pneumonia risk factors [70–72]. Considering the
elevation of Ecuador, we aimed to explore possible differences in clinical presentation and
socio-demographic factors among the prominent pathogens detected in our sample. Specifi-
cally, associations between baseline clinical factors and viral pathogens were found for RSV,
HPIV-3, and influenza A. Our results indicated that an increased respiratory rate at the time of
hospital admission was associated with decreased odds of HPIV-3. In contrast, we also found
that increase in pulse oximetry percentage was associated with decreased odds of influenza A.
Previous studies conducted in Colombia and Peru showed that low oximetry was a better indi-
cator of pneumonia than fast breathing, and that Andean Peruvian children are at higher risk
for hypoxia with ARI because of the high altitude [30,73]. Howard et al [74] similarly described
the impact of high altitude on lower baseline oxygen saturation, impaired respiratory ciliary
function, pulmonary vasoconstriction, and susceptibility to respiratory illness among children
in Peru. Thus, we hypothesized that the associations we found in Ecuador between viral pneu-
monia and pulse oximetry may result from high altitude, among many factors contributing to
hypoxemia.
Lastly, the associations found between being underweight and increased odds of RSV, and
between years of maternal education and decreased odds of influenza A support the role of
socio-demographic characteristics as risk factors for pneumonia. In our study, underweight
(weight-for-age z score <2 standard deviations) was considered a marker of undernutrition in
line with current literature [72,75,76]. A meta-analysis conducted by Jackson et al [75]
described 6 studies in developing countries that reported an association between being under-
weight and risk of severe ARI, while recent studies have described low birth weight as a risk
factor for severe RSV infection among children [77–79]. However, the association between
being underweight and RSV infection, particularly among cases of severe pneumonia, remains
unclear. Similarly, there are few studies directly exploring an association between maternal
education and influenza A among cases of severe pneumonia. Nonetheless, maternal educa-
tion as a risk factor for severe, community-acquired pneumonia has been described in devel-
oping countries [70,80,81].
At the time our study was planned and implemented, the role of human rhinovirus/entero-
virus (HRV/ENT) and human bocavirus (hBoV) as etiological agents for pneumonia, particu-
larly severe pneumonia, was uncertain. Traditionally, HRV/ENT has been associated with
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upper respiratory tract infections, especially the common cold [82–84]. However, recent litera-
ture has established these pathogens as causative organisms for lower respiratory tract infec-
tion and community-acquired pneumonia [83,85,86]. In addition, the detection of HRV/ENT
among asymptomatic individuals with acute lower respiratory infection has complicated inter-
pretation of the role of these viruses in respiratory infections [74,87]. Furthermore, although
hBoV is relatively a newly described pathogen as a cause of community-acquired pneumonia
[83,85,88], its clinical significance and etiological role requires further clarification
[42,87,89,90]. Since neither HRV/ENT nor hBoV were well described as causes of childhood
pneumonia when our study was designed, these pathogens were not included in the PCR test-
ing we decided to use for determining severe pneumonia etiology.
Strengths of our study included the standardized definition of pneumonia, close monitor-
ing of respiratory signs, training of the study team, and standardization of laboratory measure-
ment techniques [20]. Limitations were a lack of community-matched controls and routine
bacteriologic test procedures (e.g., blood cultures, induced-sputum Gram stain and culture).
The original study exhibited a higher early dropout rate than anticipated, but this was
addressed by increasing the sample size [20]. Furthermore, although not widely implemented,
PCR was used to test for S. pneumoniae, which has recently shown high sensitivity in the detec-
tion of pneumococcal pneumonia [91,92]. In this study, however, we could not serotype S.
pneumoniae isolates. In addition, the use of nasopharyngeal samples to detect viral pathogens
provides only indirect evidence of pneumonia etiology. This method was utilized because
obtaining pulmonary samples from lower airways and blood samples from children would
have been logistically challenging and overly invasive. Finally, a limited number of cases for
some pathogens constrained interpretation of seasonal trends.
In conclusion, our study describes the bacterial and viral etiology as well as manifestations
of co-infection attributable to pediatric pneumonia in Ecuador. Notably, results from the pres-
ent study illustrate the need for an RSV vaccine, and suggest increased coverage of the influ-
enza vaccine for children in Ecuador as well. Our findings of overlapping circulation patterns
of RSV and bacteremic pneumonia, particularly during the rainy season, provide information
that may help to understand and predict the impact of vaccines for RSV (future) and S. pneu-
moniae in this region. Furthermore, the isolation of demographic and clinical risk factors for
viral pathogens emphasizes the need for additional research in this area specific to climate and
altitude in the Andean region. This work provides an important foundation for further studies
in this region that are critically needed to develop improved strategies for the treatment and
prevention of pneumonia among Latin American children.
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